Tylvalosin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Tylvalosin
Accession Number
DB11554
Type
Small Molecule
Groups
Vet approved
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Tylvalosin tartrateAL5667FY0W63428-13-7Not applicable
Categories
UNII
9T02S42WQO
CAS number
Not Available
Weight
Average: 1042.267
Monoisotopic: 1041.587229585
Chemical Formula
C53H87NO19
InChI Key
KCJJINQANFZSAM-HZDSEHBESA-N
InChI
InChI=1S/C53H87NO19/c1-16-38-36(26-65-52-49(64-15)48(63-14)44(60)31(7)67-52)22-28(4)17-18-37(57)29(5)23-35(19-20-55)46(30(6)39(69-34(10)56)24-41(59)70-38)73-51-45(61)43(54(12)13)47(32(8)68-51)72-42-25-53(11,62)50(33(9)66-42)71-40(58)21-27(2)3/h17-18,20,22,27,29-33,35-36,38-39,42-52,60-62H,16,19,21,23-26H2,1-15H3/b18-17+,28-22+/t29-,30+,31-,32-,33+,35+,36-,38-,39-,42+,43-,44-,45-,46-,47-,48-,49-,50+,51+,52-,53-/m1/s1
IUPAC Name
(2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6R)-6-{[(4R,5S,6S,7R,9R,11E,13E,15R,16R)-4-(acetyloxy)-16-ethyl-15-({[(2R,3R,4R,5R,6R)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-5,9,13-trimethyl-2,10-dioxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-4-hydroxy-2,4-dimethyloxan-3-yl 3-methylbutanoate
SMILES
[H]\C1=C([H])/C(=O)[C@]([H])(C)C[C@]([H])(CC=O)[C@]([H])(O[C@]2([H])O[C@]([H])(C)[C@@]([H])(O[C@@]3([H])C[C@@](C)(O)[C@@]([H])(OC(=O)CC(C)C)[C@]([H])(C)O3)[C@]([H])(N(C)C)[C@@]2([H])O)[C@@]([H])(C)[C@@]([H])(CC(=O)O[C@]([H])(CC)[C@@]([H])(CO[C@]2([H])O[C@]([H])(C)[C@@]([H])(O)[C@@]([H])(OC)[C@@]2([H])OC)C([H])=C1C)OC(C)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Tylvalosin.
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Tylvalosin.
3-isobutyl-1-methyl-7H-xanthineThe metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Tylvalosin.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Tylvalosin.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Tylvalosin.
7-DeazaguanineThe metabolism of 7-Deazaguanine can be decreased when combined with Tylvalosin.
7,9-DimethylguanineThe metabolism of 7,9-Dimethylguanine can be decreased when combined with Tylvalosin.
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Tylvalosin.
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Tylvalosin.
9-DeazaguanineThe metabolism of 9-Deazaguanine can be decreased when combined with Tylvalosin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Guedes RM, Franca SA, Machado GS, Blumer MA, da Costa Cruz EC Jr: Use of tylvalosin-medicated feed to control porcine proliferative enteropathy. Vet Rec. 2009 Sep 19;165(12):342-5. [PubMed:19767637]
  2. Forrester CA, Bradbury JM, Dare CM, Domangue RJ, Windsor H, Tasker JB, Mockett AP: Mycoplasma gallisepticum in pheasants and the efficacy of tylvalosin to treat the disease. Avian Pathol. 2011 Dec;40(6):581-6. doi: 10.1080/03079457.2011.618822. [PubMed:22107092]
  3. Cerda RO, Petruccelli M, Piscopo M, Origlia J, Landoni M: Impact of the type of catheter on the absorption of tylvalosin (acetylvaleryltylosin) administered orally to broiler chickens. J Vet Pharmacol Ther. 2010 Apr;33(2):202-3. doi: 10.1111/j.1365-2885.2009.01103.x. [PubMed:20444046]
  4. Garces-Narro C, Barragan JI, Soler MD, Mateos M, Lopez-Mendoza MC, Homedes J: Efficacy of low-dose tylvalosin for the control of clostridiosis in broilers and its effect on productive parameters. Poult Sci. 2013 Apr;92(4):975-8. doi: 10.3382/ps.2012-02750. [PubMed:23472021]
  5. Bohm DA, Stachel CS, Gowik P: Validation of a multi-residue method for the determination of several antibiotic groups in honey by LC-MS/MS. Anal Bioanal Chem. 2012 Jul;403(10):2943-53. doi: 10.1007/s00216-012-5868-z. Epub 2012 Feb 26. [PubMed:22367248]
  6. Svartstrom O, Karlsson F, Fellstrom C, Pringle M: Characterization of Treponema spp. isolates from pigs with ear necrosis and shoulder ulcers. Vet Microbiol. 2013 Oct 25;166(3-4):617-23. doi: 10.1016/j.vetmic.2013.07.005. Epub 2013 Jul 17. [PubMed:23948134]
  7. Duinhof TF, Dierikx CM, Koene MG, van Bergen MA, Mevius DJ, Veldman KT, van Beers-Schreurs HM, de Winne RT: [Multiresistant Brachyspira hyodysenteriae in a Dutch sow herd]. Tijdschr Diergeneeskd. 2008 Jul 15-Aug 1;133(14-15):604-8. [PubMed:18767301]
  8. Hidalgo A, Carvajal A, Vester B, Pringle M, Naharro G, Rubio P: Trends towards lower antimicrobial susceptibility and characterization of acquired resistance among clinical isolates of Brachyspira hyodysenteriae in Spain. Antimicrob Agents Chemother. 2011 Jul;55(7):3330-7. doi: 10.1128/AAC.01749-10. Epub 2011 May 9. [PubMed:21555771]
  9. Pringle M, Landen A, Unnerstad HE, Molander B, Bengtsson B: Antimicrobial susceptibility of porcine Brachyspira hyodysenteriae and Brachyspira pilosicoli isolated in Sweden between 1990 and 2010. Acta Vet Scand. 2012 Sep 21;54:54. doi: 10.1186/1751-0147-54-54. [PubMed:22998753]
  10. Tavio MM, Poveda C, Assuncao P, Ramirez AS, Poveda JB: In vitro activity of tylvalosin against Spanish field strains of Mycoplasma hyopneumoniae. Vet Rec. 2014 Nov 29;175(21):539. doi: 10.1136/vr.102458. Epub 2014 Sep 2. [PubMed:25185108]
External Links
ChemSpider
4945313
ChEMBL
CHEMBL2103834

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0361 mg/mLALOGPS
logP3.8ALOGPS
logP4.63ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)7.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area250.81 Å2ChemAxon
Rotatable Bond Count19ChemAxon
Refractivity264.29 m3·mol-1ChemAxon
Polarizability110.67 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / Disaccharides / O-glycosyl compounds / Tricarboxylic acids and derivatives / Fatty acid esters / Oxanes / Alpha-hydrogen aldehydes / Tertiary alcohols / 1,2-aminoalcohols / Trialkylamines
show 11 more
Substituents
Aminoglycoside core / Macrolide / Disaccharide / Glycosyl compound / O-glycosyl compound / Tricarboxylic acid or derivatives / Fatty acid ester / Fatty acyl / Oxane / Alpha-hydrogen aldehyde
show 26 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. [PubMed:11020135]

Drug created on February 26, 2016 10:46 / Updated on June 04, 2019 07:23